News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protalix Biotherapeutics, Inc. (PLX) Release: UPLYSO™ (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease


4/29/2013 11:40:57 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CARMIEL, Israel, April 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) and the Public Health Institute of Chile have both granted regulatory approval to UPLYSO™ (alfataliglicerase) for the long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease. UPLYSO will be marketed in Mexico and Chile by Pfizer Inc., the Company's commercialization partner.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES